Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 6, 2001, Pages 481-487

  Sato, Mitsuo ^a   Ando, Masahiko ^a   Minami, Hironobu ^a   Ando, Yuichi ^a   Ando, Maki ^a   Yamamoto, Masashi ^a   Sakai, Shuzo ^a   Watanabe, Atsushi ^a   Ikeda, Takuya ^a   Sekido, Yoshitaka ^a   Saka, Hideo ^a   Shimokata, Kaoru ^a   Hasegawa, Yoshinori ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Carboplatin; Irinotecan; Lung cancer; Pharmacodynamics; Pharmacokinetics

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HIGH RISK POPULATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTIVARIATE ANALYSIS; NEUTROPENIA; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME;

EID: 0035209595     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100355     Document Type: Article

References (39)

1. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing
2. Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule
3. Early clinical studies with cis-diammine-l, l-cyclobutane dicarboxylate platinum II
4. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer
5. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials
6. Prediction of carboplatin clearance from standard morphological and biological patient characteristics
7. Prediction of creatinine clearance from serum creatinine
8. Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin
9. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum
10. Modeling toxicity and response in carboplatin-based combination chemotherapy
11. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers
12. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
13. Metabolic rate of irinotecan in humans: Correlation of glucuronidation with diarrhea
14. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients
15. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer
16. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
17. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse
18. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861
19. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin
20. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer
21. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)- 1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors
22. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry
23. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer
24. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer
25. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer
26. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer
27. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study
28. A new international staging system for lung cancer
29. Randomized phase III study of irinotecan (CPT-11) and cisplatin versus etoposide and cisplatin in extensive-disease small-cell lung cancer
30. Phase I study and pharmacokinetics of CPT11 with 5-day continuous infusion
31. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma
32. Phase I and pharmacokinetic trial of weekly CPT-11
33. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks
34. Interaction modeling of propofol and sufentanil on loss of consciousness
35. A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer
36. Optimal two-stage designs for phase II clinical trials
37. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer
38. Toxicity grading criteria of the Japan Clinical Oncology Group